Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.

Future oncology (London, England) - 1 Apr 2013

Fakih Marwan

Abstract excerpt

The targeting of EGF receptors (EGFRs) in metastatic colorectal cancer has improved the outcome of patients with KRAS wild-type tumors. However, these improvements have been modest and do not translate across all patients with KRAS wild-type tumors. Better understanding of the EGFR pathway has led to the exploration of variable novel potential biomarkers of resistance and response to anti-EGFR therapy. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-met

Share to PTEN Phosphohydrolase

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Source

Identifiers

PMID: 23560377
DOI: 10.2217/fon.12.204

Genes

KRAS
EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.PMID 23560377Read ↗

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Semantic proximity Read ↗

Markers of resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer.Semantic proximity Read ↗

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Semantic proximity Read ↗

Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.Semantic proximity Read ↗

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just geneticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.